Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids
Open accessThe DOI matches its Crossref record.
Abstract
Background—Type 1 gastric carcinoids are associated with hypergastrinaemia and chronic atrophic gastritis, type 2 occur in patients with multiple endocrine neoplasia type 1 combined with Zollinger-Ellison syndrome, and type 3 lack any relation to hypergastrinaemia. Type 1 tumours are usually benign whereas type 3 are highly malignant. Aims—To identify possible tumour markers in patients with gastric carcinoids. Patients/method—Nine patients with type 1, one with type 2, and five with type 3 were evaluated with regard to symptoms, hormone profile, and prognosis. Results—Plasma chromogranin A was increased in all patients but was higher (p<0.01) in those with type 3 than those with type 1 carcinoids. All patients with type 3 carcinoids died from metastatic disease, but none of the type 1 patients died as a result of their tumours. One type 1 patient with a solitary liver metastasis received interferon α and octreotide treatment. Nine months later, the metastasis was no longer detectable. She is still alive eight years after diagnosis, without recurrent disease. This represents the only reported case of foregut carcinoid with an unresectable liver metastasis that seems to be have been cured by biotherapy. Conclusions—Plasma chromogranin A appears to be a valuable tumour marker for all types of gastric carcinoid. Combination therapy with interferon α and octreotide may be beneficial in patients with metastasising type 1 gastric carcinoids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ramage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V, et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300831 · Cited by 952
The diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0014 · Cited by 674
Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
Modlin, I. M., Gustafsson, B. I., Moss, S. F., Pavel, M., Tsolakis, A. V., & Kidd, M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1006-3 · Cited by 387
Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours
Pape, U.-F., Berndt, U., Muller-Nordhorn, J., Bohmig, M., Roll, S., Koch, M., Willich, S. N., & Wiedenmann, B. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0017 · Cited by 384
Rindi, G., Azzoni, C., Rosa, S. L., Klersy, C., Paolotti, D., Rappel, S., Stolte, M., Capella, C., Bordi, C., & Solcia, E. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70174-5 · Cited by 354
Metadata
- Authors
- Granberg, D., Wilander, E., Stridsberg, M., Granerus, G., Skogseid, B., & Öberg, K.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 1998-08-01
- Volume
- 43
- Issue
- 2
- Pages
- 223-228
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2115025164
- Cited by
- 105
- References
- 0
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids. https://app.cochat.ai/papers/10.1136/gut.43.2.223
- The paper
- Granberg, D., Wilander, E., Stridsberg, M., Granerus, G., Skogseid, B., & Öberg, K. (1998). Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids. Gut. https://doi.org/10.1136/gut.43.2.223
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.